|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 RAs have an overall neutral effect on HF outcomes.
|
31816162 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The benefits with GLP-1 RAs are most likely derived through the reduction of atherosclerosis-related events while SGLT-2is seem mostly to reduce heart failure-related events.
|
31778747 |
2020 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptor agonist treatment reduced all-cause mortality by 12% (0·88, 0·83-0·95; p=0·001), hospital admission for heart failure by 9% (0·91, 0·83-0·99; p=0·028), and a broad composite kidney outcome (development of new-onset macroalbuminuria, decline in estimated glomerular filtration rate [or increase in creatinine], progression to end-stage kidney disease, or death attributable to kidney causes) by 17% (0·83, 0·78-0·89; p<0·0001), mainly due to a reduction in urinary albumin excretion.
|
31422062 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SGLT-2 inhibitors and GLP-1 RAs significantly reduced MACE (OR 0.88, 95% CI 0.82-0.95 and OR 0.87, 95% CI 0.82-0.93), hospitalisation for HF (OR 0.68, 95% CI 0.61-0.77 and OR 0.87, 95% CI 0.82-0.93), and renal composite outcome (OR 0.59, 95% CI 0.52-0.67 and OR 0.86, 95% CI 0.78-0.94) compared to placebo, but SGLT-2 inhibitors reduced hospitalisation for HF (OR 0.79, 95% CI 0.69-0.90) and renal composite outcome (OR 0.69, 95% CI 0.59-0.80) more than GLP-1 RAs.
|
31462224 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In comparison, GLP-1 RA appear to preferentially reduce ischemic events (stroke or myocardial infarction) over hospitalization for heart failure, and demonstrated renoprotection in several of the CVOTs.
|
31436559 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acute infusion of GLP-1 has a neutral hemodynamic effect, when assessed by thermodilution, in patients with heart failure.
|
30598343 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure.
|
30794833 |
2019 |
|
Heart failure
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Initially, the upregulation of miR-665, downregulation of GLP1R, and inactivation of cAMP signaling pathway were observed in HF rats.GLP1R was a target of miR-665.
|
30666648 |
2019 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Five completed CVOTs with the GLP-1 RAs lixisenatide (ELIXA), liraglutide (LEADER), semaglutide (SUSTAIN-6), exenatide once weekly (EXSCEL) and albiglutide (HARMONY) also failed to reveal any significant effect on HF risk.
|
30609236 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D).
|
31440988 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
In T2D, SGLT-2i can reduce the risk of HF that is unrelated to improved glycemic control; DPP-4i and GLP-1 RAs behave as neutral.
|
31028667 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide (GLP-1) is a naturally occurring incretin used as a promising therapeutic agent in the treatment of acute myocardial infarction, dilated cardiomyopathy, and advanced heart failure.
|
30503377 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy.
|
31779634 |
2019 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prior studies with DPP-IV inhibitors, thiazolidinediones (TZDs), and GLP-1 agonists have demonstrated either a neutral effect on HF or increased HF hospitalizations.
|
30259198 |
2018 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neither glucagon-like preptide-1 (GLP-1) receptor agonists, nor dipeptidyl peptidase-4 (DPP4) inhibitors reduce the risk for HF hospitalization.
|
29520964 |
2018 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unlike GLP-1R agonists, signaling for HF adverse effects was observed with two DPP-4 inhibitors, saxagliptin and alogliptin.
|
29682682 |
2018 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consequently, GLP-1 RA drugs in addition to conventional hypoglycemic therapy may reduce hospital admissions for heart failure worsening, by increasing CRTd responders rate.Trial registration NCT03282136.
|
30348145 |
2018 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are concerns that incretin-based antidiabetic drugs - including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists - increase the risk of hospitalization for heart failure (HF).
|
30332619 |
2018 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might show benefits on endothelial function, coronary ischaemia, and heart failure.
|
29805980 |
2018 |
|
Heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current evidence suggests that SGLT-2 inhibitors are more effective than either GLP-1 agonists or DPP-4 inhibitors for reducing the risk of hospitalization for HF in type 2 diabetes mellitus.
|
30196071 |
2018 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
No significant effect of GLP-1 receptor agonists was identified on fatal and non-fatal myocardial infarction, fatal and non-fatal stroke, hospital admission for unstable angina, or hospital admission for heart failure.
|
29221659 |
2018 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neprilysin inhibitors may also be able to augment the effects of long-acting GLP-1 analogues to increase heart rate and myocardial cyclic AMP, and thus, potentiate these deleterious actions; if so, concomitant treatment with GLP-1 receptor agonists may limit the efficacy of neprilysin inhibitors in patients with both heart failure and diabetes.
|
29603541 |
2018 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The GLP-1 agonist liraglutide was recently shown to reduce cardiovascular and all-cause mortality, yet hospitalization for HF was not significantly reduced.
|
27653447 |
2017 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Findings from recently completed trials indicate that a GLP-1 RA-induced increase in HR, regardless of magnitude, does not present an increased cardiovascular risk for subjects with T2DM, although a pronounced increase in HR may be associated with adverse clinical outcomes in those with advanced heart failure.
|
28086882 |
2017 |
|
Heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Disturbances in calcium cycling are characteristic of heart failure (HF); therefore, the aim of this study was to investigate the effect of exendin-4 (a GLP-1 mimetic) on the regulation of calcium handling and to identify the underlying mechanisms in an HF rat model after myocardial infarction (MI).
|
28242257 |
2017 |